Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Arvinas Inc. Arvinas to Participate in Upcoming Investor Conferences November 04, 2024 From Arvinas Inc. Via GlobeNewswire Tickers ARVN Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update October 30, 2024 From Arvinas Inc. Via GlobeNewswire Tickers ARVN Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day October 22, 2024 From Arvinas Inc. Via GlobeNewswire Tickers ARVN Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024 October 21, 2024 From Arvinas Inc. Via GlobeNewswire Tickers ARVN Arvinas to Participate in Upcoming Investor Conferences August 29, 2024 From Arvinas Inc. Via GlobeNewswire Tickers ARVN Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update July 30, 2024 From Arvinas Inc. Via GlobeNewswire Tickers ARVN NVS Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer June 24, 2024 From Arvinas Inc. Via GlobeNewswire Tickers ARVN Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2 June 21, 2024 From Arvinas Inc. Via GlobeNewswire Tickers ARVN Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer June 17, 2024 From Arvinas Inc. Via GlobeNewswire Tickers ARVN Arvinas to Participate in Upcoming Investor Conferences June 03, 2024 From Arvinas Inc. Via GlobeNewswire Tickers ARVN Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress May 23, 2024 From Arvinas Inc. Via GlobeNewswire Tickers ARVN Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) May 16, 2024 From Arvinas Inc. Via GlobeNewswire Tickers ARVN PFE Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress May 09, 2024 From Arvinas Inc. Via GlobeNewswire Tickers ARVN Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update May 07, 2024 From Arvinas Inc. Via GlobeNewswire Tickers ARVN NVS Arvinas to Present at Upcoming Investor Conferences May 02, 2024 From Arvinas Inc. Via GlobeNewswire Tickers ARVN Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer April 24, 2024 From Arvinas Inc. Via GlobeNewswire Tickers ARVN Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer April 11, 2024 From Arvinas Inc. Via GlobeNewswire Tickers ARVN NVS Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer March 18, 2024 From Arvinas Inc. Via GlobeNewswire Tickers ARVN Arvinas to Participate in Upcoming Investor Conferences March 04, 2024 From Arvinas Inc. Via GlobeNewswire Tickers ARVN Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update February 27, 2024 From Arvinas Inc. Via GlobeNewswire Tickers ARVN Arvinas Announces Chief Financial Officer Transition February 20, 2024 From Arvinas Inc. Via GlobeNewswire Tickers ARVN Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease February 20, 2024 From Arvinas Inc. Via GlobeNewswire Tickers ARVN Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer February 06, 2024 From Arvinas Inc. Via GlobeNewswire Tickers ARVN PFE Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference February 01, 2024 From Arvinas Inc. Via GlobeNewswire Tickers ARVN Arvinas Appoints Jared Freedberg as General Counsel January 16, 2024 From Arvinas Inc. Via GlobeNewswire Tickers ARVN Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program December 05, 2023 From Arvinas Inc. Via GlobeNewswire Tickers ARVN Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program December 05, 2023 From Arvinas Inc. Via GlobeNewswire Tickers ARVN PFE Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium November 28, 2023 From Arvinas Inc. Via GlobeNewswire Tickers ARVN PFE Arvinas Announces Oversubscribed $350 Million Private Placement November 27, 2023 From Arvinas Inc. Via GlobeNewswire Tickers ARVN Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update November 07, 2023 From Arvinas Inc. Via GlobeNewswire Tickers ARVN Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
